Andrew Green
Endocrinology, Diabetes & Metabolism · Shawnee Mission, KSNPI 1255325791
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $290,605 of the $322,471 with a category attached, or 90.1%. Novo Nordisk accounts for 61.6% of it on its own, with 38 other manufacturers making up the rest. Reporting peaked in 2019 at $119,457 and has fallen 100.0% since, to $57 in 2025. Among endocrinology, diabetes & metabolism clinicians in KS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 885 payments — averaging $364.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$199K
- Boehringer Ingelheim$53K
- Lilly USA, LLC$43K
- AbbVie$12K
- Johnson & Johnson$7K
- Mannkind Corporation$5K
- plus $4K from 33 others
What the payments were for
- Consulting fees$5,6882%
- Speaking & faculty fees$290,60590%
- Travel & lodging$12,9654%
- Food & beverage$13,1804%
- Education$340%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 342 | $198,550 |
| Boehringer Ingelheim | 95 | $53,084 |
| Lilly USA, LLC | 131 | $42,689 |
| AbbVie | 43 | $11,582 |
| Johnson & Johnson | 10 | $7,161 |
| Mannkind Corporation | 11 | $5,050 |
| Abbott | 39 | $576 |
| AstraZeneca(2 entities) | 28 | $458 |
| Pfizer | 21 | $341 |
| Sanofi-aventis U.S. LLC | 21 | $301 |
| Merck | 19 | $289 |
| Bayer | 10 | $274 |
| Insulet Corporation | 11 | $259 |
| Corcept Therapeutics | 13 | $256 |
| Amgen(2 entities) | 14 | $224 |
| Radius Health, Inc. | 9 | $222 |
| Ascensia Diabetes Care US Inc. | 11 | $207 |
| Amarin Pharma, Inc. | 14 | $202 |
| Amneal Pharmaceuticals LLC | 10 | $151 |
| Dexcom, Inc. | 5 | $136 |
| Tandem Diabetes Care, Inc. | 4 | $75 |
| Medtronic(2 entities) | 4 | $58 |
| Ipsen Biopharmaceuticals, Inc | 2 | $37 |
| Esperion Therapeutics, Inc. | 2 | $33 |
| Clarus Therapeutics Inc. | 2 | $25 |
| Cequr Corporation | 1 | $22 |
| Ultragenyx Pharmaceutical Inc. | 1 | $21 |
| Xeris Pharmaceuticals, Inc. | 1 | $20 |
| Shire North American Group Inc | 1 | $18 |
| Endo Pharmaceuticals Inc. | 1 | $17 |
| Almatica Pharma LLC | 1 | $17 |
| Companion Medical, Inc. | 1 | $16 |
| Antares Pharma, Inc. | 1 | $16 |
| Aegerion Pharmaceuticals, Inc. | 1 | $15 |
| Zealand Pharma US, Inc. | 1 | $15 |
| IBSA Pharma Inc. | 1 | $14 |
| Vivus LLC | 1 | $14 |
| Sanofi Pasteur Inc. | 1 | $13 |
| Nevro Corp. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$322,471 in reported general payments places this provider in the 95th percentile of 50 endocrinology, diabetes & metabolism providers in Kansas.
See all endocrinology, diabetes & metabolism providers in Kansas →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 24 | $31,598 |
| JardianceEmpagliflozin | 15 | $17,483 |
| Metformin Hcl | 18 | $126 |
| Rosuvastatin Calcium | 14 | $119 |
| Atorvastatin Calcium | 17 | $88 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $198,550 | $31,59824 claims |
| Boehringer IngelheimJardiance | $53,084 | $17,48315 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 50 endocrinology, diabetes & metabolism providers in Kansas.
Other endocrinology, diabetes & metabolism in Shawnee Mission
- John LiuShawnee Mission$8K
- Dany ZayourWichita$744K
- Michael SokolOverland Park$227K
- Rami MortadaWichita$105K
- Sajeev MenonOverland Park$25K
- Georges ElhomsyWichita$14K
- Richard GomendozaSalina$13K
- John MilesKansas City$13K
- Nichole SmithMerriam$9K
- Susan BrianTopeka$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.